US20220409626A1 - Tablets for oral suspension containing rivaroxaban - Google Patents
Tablets for oral suspension containing rivaroxaban Download PDFInfo
- Publication number
- US20220409626A1 US20220409626A1 US17/501,519 US202117501519A US2022409626A1 US 20220409626 A1 US20220409626 A1 US 20220409626A1 US 202117501519 A US202117501519 A US 202117501519A US 2022409626 A1 US2022409626 A1 US 2022409626A1
- Authority
- US
- United States
- Prior art keywords
- tablet
- binder
- rivaroxaban
- formulation
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940100692 oral suspension Drugs 0.000 title claims abstract description 25
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 title claims description 79
- 229960001148 rivaroxaban Drugs 0.000 title claims description 73
- 239000000203 mixture Substances 0.000 claims abstract description 121
- 238000009472 formulation Methods 0.000 claims abstract description 86
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 23
- 238000004090 dissolution Methods 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000000314 lubricant Substances 0.000 claims abstract description 19
- 239000007884 disintegrant Substances 0.000 claims abstract description 18
- 239000000080 wetting agent Substances 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 239000011230 binding agent Substances 0.000 claims description 41
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 37
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 35
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 29
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 29
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 29
- 239000000725 suspension Substances 0.000 claims description 26
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 23
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 21
- 239000008187 granular material Substances 0.000 claims description 21
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 21
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 18
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 16
- 238000005469 granulation Methods 0.000 claims description 16
- 230000003179 granulation Effects 0.000 claims description 16
- 229960001021 lactose monohydrate Drugs 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 15
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 15
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 12
- 229960000913 crospovidone Drugs 0.000 claims description 12
- 239000000945 filler Substances 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 12
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 12
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 12
- 229960003943 hypromellose Drugs 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 238000005550 wet granulation Methods 0.000 claims description 10
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical group CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 9
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 239000007916 tablet composition Substances 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 7
- 208000029078 coronary artery disease Diseases 0.000 claims description 7
- 208000010125 myocardial infarction Diseases 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 6
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 6
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 6
- 206010047249 Venous thrombosis Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 208000030613 peripheral artery disease Diseases 0.000 claims description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 6
- 235000012239 silicon dioxide Nutrition 0.000 claims description 6
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 5
- 229920001983 poloxamer Polymers 0.000 claims description 5
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 3
- 208000005189 Embolism Diseases 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 239000000454 talc Substances 0.000 claims description 3
- 229910052623 talc Inorganic materials 0.000 claims description 3
- 235000012222 talc Nutrition 0.000 claims description 3
- 238000003801 milling Methods 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 239000012071 phase Substances 0.000 description 27
- 239000002552 dosage form Substances 0.000 description 17
- 235000010980 cellulose Nutrition 0.000 description 13
- 229920002678 cellulose Polymers 0.000 description 13
- 239000001913 cellulose Substances 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 10
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229960001375 lactose Drugs 0.000 description 10
- 239000008101 lactose Substances 0.000 description 10
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 10
- 229910052710 silicon Inorganic materials 0.000 description 10
- 239000010703 silicon Substances 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 229910052708 sodium Inorganic materials 0.000 description 10
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 229910021653 sulphate ion Inorganic materials 0.000 description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 7
- 208000006011 Stroke Diseases 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229940032147 starch Drugs 0.000 description 6
- 238000013459 approach Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229940055725 xarelto Drugs 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 3
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 3
- 238000007908 dry granulation Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000007211 cardiovascular event Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009506 drug dissolution testing Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000009477 fluid bed granulation Methods 0.000 description 2
- 239000013022 formulation composition Substances 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 2
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 2
- 239000008384 inner phase Substances 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 238000007909 melt granulation Methods 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(e)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- -1 glidant Substances 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000009725 powder blending Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000009491 slugging Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 235000021058 soft food Nutrition 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Definitions
- This patent document discloses a novel formulation of rivaroxaban or its pharmaceutically acceptable salt, a method for its preparation and its use in medical therapy.
- Rivaroxaban is marketed in the United States by Janssen Pharmaceuticals, Inc., under the trade name XARELTO®, XARELTO is for the indication of reducing the risk of stroke and blood clots, treating blood clots in the veins, helping prevent blood clots, and also reducing the risk of serious heart problems, heart attack and stroke in people with coronary artery disease.
- XARELTO is an immediate release tablet. There are no liquid formulations of rivaroxaban commercially available and, as a result, pharmacists are often required to compound liquid formulations using crushed rivaroxaban tablets for pediatric patients and patients who cannot swallow tablets, for example, acutely ill medical patients who need medicine administered via an NG tube or gastric feeding tube. A need exists for an improved formulation of Rivaroxaban.
- Tablets for oral suspension formulation described herein allows for convenient oral administration of Rivaroxaban.
- the formulation resolved the dose inaccuracy issue due to the crushed step and precipitation of big crushed particles in a suspension system,
- tablets for oral suspension do not require professionals to crush the tablet and can be dispersed in the vehicles to form suspension immediately before use, which is much convenient for patients and professionals.
- the tablets for oral suspension formulation substantially improves the stability of the medication compared to the ready-to-use suspension.
- An aspect of this patent document provides tablets for oral suspension formulation suitable for reconstitution with a pharmaceutically acceptable carrier to form a suspension.
- the formulation contains rivaroxaban or a pharmaceutically acceptable salt thereof, and excipients including for example disintegrant agent, lubricant, glidant, binder, wetting agent, and filler.
- the rivaroxaban tablets for oral suspension can disintegrate rapidly within about 3 minutes in 100 ml water at room temperature, and the reconstituted suspension can pass through mesh aperture of 710 ⁇ m, furthermore, the tablet provides an in vitro release of at least about 75% of the rivaroxaban within about 30 minutes under USP dissolution apparatus 2, in 900 ml of pH14.5 media (2.5 mg) or with 0.2% SLS (for 10 mg strength) or 0.4% SLS (for 15 mg and 20 mg strength) at 75 rpm stirring rate.
- rivaroxaban or a pharmaceutically acceptable salt is present ranging about 1 mg to about 50 mg in the tablet.
- rivaroxaban or a pharmaceutically acceptable salt is present ranging about 1% to about 30% in the tablet.
- the disintegrant agent is present ranging from about 5% to about 15% in the tablet.
- the ubricant is present ranging from about 0.5% to about 5% in the tablet.
- the glidant is present ranging from about 0.5% to about 3% in the tablet.
- the wetting agent is present ranging from about 0.1% to about 1% in the tablet.
- the binder is present ranging from about 1% to abort 8% in the tablet.
- the rivaroxaban or the pharmaceutically acceptable salt thereof and the wetting agent have a ratio ranging from about 20:0.1 to about 1:1 by weight.
- the rivaroxaban or the pharmaceutically acceptable salt thereof and the binder have a ratio ranging from about 20:0.5 to about 1:1 by weight.
- the disintegrant agent is selected from starch, crosslinked polyvinylpyrrolidone (crospovidone), crosslinked sodium carboxymethyl cellulose (croscarmellose sodium), the modified starch sodium starch glycolate and any combination thereof. In some embodiments, the disintegrant agent is crospovidone.
- the dosage form further contains a lubricant selected from the group consisting of magnesium stearate, stearic acid, sodium stearyl fumarate, and sodium lauryl sulfate, glyceryl palmitostearate, and any combination thereof.
- the lubricant is sodium stearyl fumarate.
- the formulation further contains glidants including for example silicon dioxide, starch, talc and any combination thereof.
- the glidant is silicon dioxide.
- the formulation further contains the wetting agent including for example sodium dodecyl sulfate (SDS) or sodium lauryl sulfate (SLS), poloxamers or pluronics, tween 80 and any combination thereof.
- the wetting agent is sodium lauryl sulfate (SLS)
- the formulation further contains the binder including for example Polyvinylpyrrolidone (PVP), Hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC) and any combination thereof.
- the binder is Hydroxypropyl methylcellulose (HPMC).
- the formulation further contains a filler selected from the group consisting of sucrose, dextrose, mannitol, sorbitol, maltitol, starch, lactose, microcrystalline cellulose, and any combination thereof in about 10% to about 98% by weight of the tablet formulation.
- the tiller is microcrystalline cellulose and lactose, with the ratio ranging from about 5:1 to about 1:5 by weight.
- the rivaroxaban or the pharmaceutically acceptable salt thereof has a D90 ranging from about 1 ⁇ m to about 50 ⁇ m prior to being mixed with the excipients.
- a dosage form can be manufacture via wet granulation, dry granulation, dry blending, melt granulation and fluid bed granulation approach. In some embodiments, a dosage form can be manufactured via wet granulation approach in high shear granulator.
- a dosage form can be manufacture via wet granulation by adding water in the powder in high shear granulator, the amount of water is 20% to 60% of that powder for granulation by weight.
- the rivaroxaban tablets for oral suspension can disintegrate rapidly within about 3 minutes in 100 ml water at room temperature, and the reconstituted suspension can pass through mesh aperture of 710 ⁇ m.
- the tablet provides an in vitro release of at least about 75% of the rivaroxaban within about 30 minutes under USP dissolution apparatus 2, in 900 ml of pH4.5 media (2.5 mg) or with 0.2% SLS (for 10 mg strength) or 0.4% SLS (for 15 mg and 20 mg strength) at 75 rpm stirring rate.
- the tablets for oral suspension formulation provides a release of rivaroxaban bioequivalent to XARELTO tablet of the same dose.
- the suspension prepared from the tablet formulation provides a release of the rivaroxaban bioequivalent to a non-suspension dosage form (e.g. XARELTO tablet), which provides a therapeutically effective blood concentration of rivaroxaban.
- Another aspect of the patent document provides a method of treating or prophylaxis or reducing the risk of a disease comprising administering the suspension described herein to a subject in need, wherein the disease is selected from the group consisting of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE), major cardiovascular events (cardiovascular (CV) death, myocardial infarction (MI) and stroke) in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).
- the disease is selected from the group consisting of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE), major cardiovascular events (cardiovascular (CV) death, myocardial infarction (MI) and stroke) in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).
- This document discloses a tablet formulation suitable for reconstitution with a pharmaceutically acceptable carrier to form a suspension oral dosage form of rivaroxaban.
- Advantages of the tablets for oral suspension formulation include avoiding tablet crushing, dose accuracy and better compliance for pediatric patients and patients who cannot swallow tablets in comparison with conventional immediate release non-suspension dosage forms.
- Rivaroxaban is known as 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide. Rivaroxaban is insoluble in water. When crushed rivaroxaban tablets are simply added directly into water or other soft food, the compound tends to settle rapidly and cannot be easily redistributed and as such would potentially affect the dose accuracy delivered to a patient.
- the tablets for oral suspension formulation disclosed herein effectively resolved the above issues. After reconstitution, the suspension enables easy and accurate dose for pediatric patients and patients who cannot swallow tablets, for example, acutely ill medical patients who need medicine administered via an NG tube or gastric feeding tube. Further, tablets for oral suspension formulation substantially improves the stability of the medication compared to the ready-to-use suspension.
- the table for oral suspension formulation described in this patent document are applicable to Rivaroxaban as well as salts, isomers, complexes, polymorphs, hydrates, esters and prodrugs thereof.
- active ingredient or “active pharmaceutical ingredient” (API) refers to a compound (e.g. rivaroxaban) that can be used for treating a disorder or condition in a subject (e.g., a patient), or for preventing one or more symptoms of such disorder or condition in the subject.
- a compound e.g. rivaroxaban
- API active pharmaceutical ingredient
- bioequivalence refers to two formulations, dosage forms, products, or compositions of an active ingredient having biological equivalence. It is generally considered bioequivalent if the 90% Confidence Interval (“CI”) of the relative mean Cmax, AUC(0-t) and AUC(0- ⁇ ) of the test formulation to reference formulation (i.e., brand product) is within 80.0% to 125.0% in the fasting state of a tested subject.
- CI 90% Confidence Interval
- patient compliance refers to the degree to which patient correctly follows medical advice.
- excipient refers to any inert substance that may have specific functions to the active ingredient (e.g., filler agent, binder, lubricant, glidant).
- An excipient provides without limitation, bulk, consistency, stability, binding ability, lubrication, disintegrating ability, etc., to the formulation of an active ingredient.
- a “glidant” is a type of excipient. An excipient may function for multiple purposes.
- binder refers to any composition or formulation which is dry and flowable. Non-limiting examples include granules, flakes, spheroids and other forms which can be readily prepared and mixed with an ingestible liquid to provide a desirable liquid suspension.
- wet granulation refers to a process of using a liquid binder to lightly agglomerate the powder mixture.
- API refers to active pharmaceutical ingredient, which is rivaroxaban or a pharmaceutically acceptable salt.
- release when used in connection with a pharmaceutical compression or dosage form, refers to the process or the portion of the active ingredient that leaves the dosage form following contact with an aqueous environment. Unless otherwise indicated, the quantity of an active ingredient released from a dosage form is measured by dissolution testing in water as described in this invention. The results of the dissolution testing are reported as % (w/w) released as a function of time or as the release time. In some embodiments, complete release of an active ingredient occurs when at least 90% of the active ingredient has been released from the dosage form.
- immediate-release refers to those which disintegration rapidly and/or get dissolved to release the medicaments or active ingredient.
- Cmax or “peak plasma exposure”, expressed in ng/mL, refers to the point of maximum concentration of drug in plasma.
- AUC area under curve
- D90 refers to the particle size corresponding to 90% of the cumulative undersize distribution by volume.
- pharmaceutically acceptable carrier refers to an agent or a substance that enable an active ingredient or a composition thereof to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for administration to a subject in need.
- the carrier can be water or an aqueous solution containing other excipients.
- subject refers to a mammal, such as an animal or a human.
- the methods disclosed herein can be useful in human therapy and veterinary applications.
- the subject is an animal.
- the subject is a human.
- the term “treat” or “treating” refers to attain or attaining a beneficial or desired result, such as a clinical result.
- the beneficial or desired result is any one or more of the following: inhibiting or suppressing the onset or development of a condition, reducing the severity of the condition, reducing the number or severity of symptoms associated with the condition, increasing the quality of life of a patient suffering from the condition, decreasing the dose of another medication required to treat the condition, enhancing the effect of another medication a patient is taking for the condition, and prolonging the survival of a patient having the condition.
- An aspect of the document provides tablets for oral suspension formulation suitable for reconstitution with a pharmaceutically acceptable carrier to form an oral suspension of rivaroxaban.
- the formulation includes:
- Rivaroxaban a pharmaceutically acceptable salt, an isomer, a complex, a polymorph, a hydrate, or an ester thereof:
- Disintegrant agent present ranging from about 5% to about 15%
- Lubricant agent present ranging from about 0.5% to about 5%
- Glidant agent present ranging from about 0.5% to about 3%
- Wetting agent present ranging from about 0.1% to about 1%
- Binder present ranging from about 1% to about 8%
- Filler ranging from about 10% to about 98% by weight
- Wetting agent having a ratio with rivaroxaban or the pharmaceutically acceptable salt ranging from about 20:0.1 to about 1:1 by weight.
- Binder having a ratio with rivaroxaban or the pharmaceutically acceptable salt ranging from about 20:0.5 to about 1:1 by weight.
- the pharmaceutically acceptable carrier is water or an aqueous solution containing one or more agents or excipients.
- the rivaroxaban tablets for oral suspension can disintegrate rapidly within about 3 minutes (e.g. 160 seconds, 140 seconds, 120 seconds, 90 seconds, 60 seconds, or 30 seconds), within about 2 minutes (e.g. 100 seconds, 80 seconds. 60 seconds, or 30 seconds), or within about 1 minute (e.g.
- the tablet provides an in vitro release of at least about 75% of the rivaroxaban within about 30 minutes, within about 20 minutes, or within about 10 minutes under USP dissolution apparatus 2, in 900 ml of ph 4.5 media (2.5 mg) or with 0.2% SLS (for 10 mg strength) or 0.4% SLS (for 15 mg and 20 mg strength) at 75 rpm stirring rate.
- rivaroxaban or a pharmaceutically acceptable salt is present ranging from 1 mg to 50 mg.
- the tablet includes 2.5-20 mg rivaroxaban or a pharmaceutically acceptable salt thereof.
- the rivaroxaban or a pharmaceutically acceptable salt is present ranging from about 1% to about 30%, from about 1.5% to about 25%, from about 1.8% to about 22%, or from about 2% to about 18% by weight.
- the disintegrant agent is present ranging from about 5% to about 15%, from about 5% to about 14%, from about 5% to about 13%, from about 6% to about 12%, from about 6% to about 11%, from about 6% to about 10% by weight.
- the lubricant agent is present ranging from about 0.2% to about 7%, from about 0.5% to about 5%, from about 1% to about 3%, from about 1.1% to about 2.5%, from about 1.3% to about 2.2% by weight,
- the glidant agent is present ranging from about 0.5% to about 3%, from about 0.6% to about 2%, from about 0.7% to about 1.5%, from about 0.8% to about 1.2% by weigh.
- the wetting agent is present ranging from about 0.1% to about 1.2%, from about 0.1% to about 1%, from about 0.2% to about 0.8%, from about 0.2% to about 0.6% by weigh.
- the binder is present ranging from about 1% to about 8%, from about 1% to about 3.5%, from about 1.5% to about 3.5%, from about 2% to about 3% by weigh.
- the rivaroxaban or the pharmaceutically acceptable salt thereof and the wetting agent have a ratio ranging from about 20:0.1 to about 1:1, from about 20:0.2 to about 2:1, from about 20:0.3 to about 3:1, from about 20:0.4 to about 4:1 by weight.
- the rivaroxaban or the pharmaceutically acceptable salt thereof and the binder have a ratio ranging from about 20:0.5 to about 1:1 by weight, from about 20:0.8 to about 1:1, from about 20:1 to about 1:1
- the disintegrant agent is selected from starch, crosslinked polyvinylpyrrolidone (crospovidone), crosslinked sodium carboxymethyl cellulose (croscarmellose sodium), the modified starch sodium starch glycolate and any combination thereof.
- the disintegrant agent is crospovidone (Kollidon CL-F).
- the dosage form further contains a lubricant selected from the group consisting of magnesium stearate, stearic acid, sodium stearyl fumarate, and sodium lauryl sulfate, glyceryl palmitostearate, and any combination thereof.
- the lubricant is sodium stearyl fumarate.
- the formulation further contains glidants including for example silicon dioxide, starch, talc and any combination thereof.
- the glidant is silicon dioxide.
- the wetting agent is selected sodium dodecyl sulfate (SLS) or sodium lauryl sulfate (SLS), poloxamers or pluronics, tween 80 and any combination thereof. In some embodiments, the wetting agent is sodium dodecyl sulfate (SLS).
- the binder is selected from Polyvinylpyrrolidone Hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC) and any combination thereof. In some embodiments, the binder is Hydroxypropyl methylcellulose (HPMC).
- the formulation further contains a filler selected from the group consisting of sucrose, dextrose, mannitol, sorbitol, maltitol, starch, lactose, microcrystalline cellulose, and any combination thereof in about 10% to about 98%, from about 30% to about 95%, from about 45% to about 93%, from about 60% to about 90% by weight.
- the filler is microcrystalline cellulose and lactose, with the ratio ranging from about 5:1 to about 1:5, from about 4:1 to about 1:2, from about 3:1 to about 1:1, from about 2:1 to about 1: 1 by weight.
- the tablet has an inner phase and an external phase.
- the inner phase includes rivaroxaban, hydroxypropyl methylcellulose, sodium lauryl sulfate, crosslinked polyvinylpyrrolidone (crospovidone), 70-95% of the total microcrystalline cellulose, and lactose monohydrate, while the external phase includes the remaining amount of microcrystalline cellulose, colloidal silicon dioxide and lubricant.
- the ratio between the microcrystalline cellulose and the lactose monohydrate ranges from 1:1 to 2:1 or from 1.5-1.8:1 by weight. In some embodiments, substantially all of the lactose monohydrate is in the inner portion.
- the tablet by weight includes 1.0%-30.0% rivaroxaban, 1,0%-8.0% hydroxypropyl methylcellulose, 0.1-1% sodium lauryl sulfate, 5%-15.0% crosslinked polyvinylpyrrolidone (crospovidone), 0.5%-3.0% colloidal silicon dioxide, 0.5%-5% lubricant (e.g. magnesium stearate or sodium stearvl fumarate), and filler (e.g. microcrystalline cellulose and the lactose monohydrate).
- crospovidone crosslinked polyvinylpyrrolidone
- colloidal silicon dioxide e.g. magnesium stearate or sodium stearvl fumarate
- filler e.g. microcrystalline cellulose and the lactose monohydrate.
- the tablet by weight includes 1.5%-25.0% rivaroxaban, 1.0%-5.0% hydroxypropyl methylcellulose, 0.2-0.8% sodium lauryl sulfate, 6.0%12.0% crosslinked polyvinylpyrrolidone (crospovidone), 0.6%-2.0% colloidal silicon dioxide, 1.0%-3.0% sodium stearyl fumarate, and microcrystalline cellulose and the lactose monohydrate as filler.
- rivaroxaban 1.0%-5.0% hydroxypropyl methylcellulose
- 0.2-0.8% sodium lauryl sulfate 6.0%12.0% crosslinked polyvinylpyrrolidone (crospovidone)
- crospovidone crosslinked polyvinylpyrrolidone
- colloidal silicon dioxide 1.0%-3.0% sodium stearyl fumarate
- microcrystalline cellulose and the lactose monohydrate as filler.
- the tablet by weight includes 1.8%-22.0% rivaroxaban, 1.5%-3.5% hydroxypropyl methylcellulose, 0.2-0.8% sodium lauryl sulfate, 6.0%-12.0% crosslinked polyvinylpyrrolidone (crospovidone), 0.7%-4.5% colloidal silicon dioxide, 1.1%-2.5% sodium stearyl fumarate, and microcrystalline cellulose and the lactose monohydrate as filler.
- rivaroxaban 1.5%-3.5% hydroxypropyl methylcellulose
- 0.2-0.8% sodium lauryl sulfate 6.0%-12.0% crosslinked polyvinylpyrrolidone (crospovidone), 0.7%-4.5% colloidal silicon dioxide, 1.1%-2.5% sodium stearyl fumarate, and microcrystalline cellulose and the lactose monohydrate as filler.
- crospovidone crosslinked polyvinylpyrrolidone
- colloidal silicon dioxide 1.1%-2.5% sodium stearyl fumarate
- the tablet by weight includes 2.0%-18.0% rivaroxaban, 2.0%-3.0% hydroxypropyl methylcellulose, 0.2-0.6% sodium lauryl sulfate, 6.0%-10.0% crosslinked polyvinylpyrrolidone (crospovidone), 0.8%1.2% colloidal silicon dioxide, 1.3%-2.2% sodium stearvl fumarate, and microcrystalline cellulose and the lactose monohydrate as filler.
- rivaroxaban 2.0%-3.0% hydroxypropyl methylcellulose
- 0.2-0.6% sodium lauryl sulfate 6.0%-10.0% crosslinked polyvinylpyrrolidone (crospovidone), 0.8%1.2% colloidal silicon dioxide, 1.3%-2.2% sodium stearvl fumarate, and microcrystalline cellulose and the lactose monohydrate as filler.
- crospovidone crosslinked polyvinylpyrrolidone
- colloidal silicon dioxide 1.3%-2.2% sodium stearvl fumarate
- the rivaroxaban or the pharmaceutically acceptable salt thereof has a D90 ranging from about 1 ⁇ m to about 50 ⁇ m, from about 2 um to about 40 um, from about 3 um to about 30 um, from about 4 um to about 20 um prior to being mixed with the excipients.
- a dosage form can be manufacture via wet granulation, dry granulation, dry blending, melt granulation and fluid bed granulation approach. In some embodiments, a dosage form can be manufactured via wet granulation approach in high shear granulator.
- a dosage form can be manufactured via wet granulation by adding from about 20% to about 60%, from about 30% to about 50% of water to the powder in high shear granulator.
- the rivaroxaban tablets for oral suspension can disintegration rapidly within 3 minutes within about 2 minutes, within about 1 minutes when dispersing in the 100 ml water at room temperature.
- the tablets for oral suspension formulation provide an in vitro release as measured by USP dissolution apparatus 2.
- at least about 95%, at least about 90%, at least about 85%, at least about 80%, at least about 75%, at least about 65% or at least about 50% of 2.5 mg rivaroxaban is released in a pH4.5 medium within about 30 minutes, within about 20 minutes, within about 10 minutes at 75 rpm stirring rate
- the tablets for oral suspension formulation provide an in vitro release as measured by USP dissolution apparatus 2.
- at least about 95%, at least about 90%, at least about 85%, at least about 80%, at least about 75%, at least about 65% or at least about 50% of 10 mg rivaroxaban is released in a pH4.5 medium with 0.2% SLS within about 30 minutes, within about 20 minutes, within about 10 minutes at 75 rpm stirring rate
- the tablets for oral suspension formulation provide an in vitro release as measured by USP dissolution apparatus 2.
- at least about 95%, at least about 90%, at least about 85%, at least about 80%, at least about 75%, at least about 65% or at least about 50% of 15 mg or 20 mg rivaroxaban is released in a pH4.5 medium with 0.4% SLS within about 30 minutes, within about 20 minutes, within about 10 minutes at 75 rpm stirring rate
- the tablets for oral suspension formulation can also provide a release of rivaroxaban bioequivalent to non-suspension formulation of rivaroxaban at the same dose.
- non-suspension formulation of rivaroxaban include rivaroxaban tablets.
- the dose of rivaroxaban in the formulation is about 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, 40 mg or 50 mg.
- the suspension can be prepared from the above described tablets for oral suspension formulation by reconstitution or by mixing the necessary components in suitable means as long as the resulting suspension achieves a desirable profile for oral administration.
- the suspension can be prepared by adding water to the above described tablets formulation containing suitable dosage of rivaroxaban or its salt and thoroughly mix the combined substances.
- the tablets for oral suspension allow for accurate dose and easy administration.
- the tablets for oral suspension formulation also have excellent stability compared to ready-to-use suspension. This is especially important for pediatric patients and patients who cannot swallow tablets, for example, acutely ill medical patients who need medicine administered via an NG tube or gastric feeding tube.
- Another aspect of the patent document provides a method of preparing the above described formulation.
- the method generally includes:
- Step 1 Dissolve wetting agent and partial binder (1 ⁇ 4-1 ⁇ 2) in certain amount of water to form solution 1
- Step 2 Pass internal phase excipient(including partial binder) through certain mesh and add them into high shear granulator Step 3 Pre-mix the internal phase excipient before adding granulation liquid
- Step 4 Add granulation fluid into excipient at certain speed while mixing Step 5 After all the granulation liquid was added, the kneading step was added for certain time
- Step 7 The dried granule pass through mill with screen of certain orifice
- Step 8 The screened granules mixed with external phase before compressed into tablets.
- Step 9 The final blend was compressed into tablets of certain hardness.
- the tablet disclosed herein is prepared according to the following method:
- Step 1 Dissolve sodium lauryl sulfate and 1 ⁇ 4-1 ⁇ 2 of total amount of hydroxypropyl methylcellulose in water to form a solution; Step 2 mix rivaroxaban, lactose monohydrate and the remaining amount of hydroxypropyl methylcellulose to obtain a mixture; Step 3 pass the mixture of step 2 through mesh; Step 4 mix the mixture of step 3 with 70-95% of microcrystalline cellulose and all crospovidone to prepare granules; Step 5 add the solution from step 1 to the granules to obtain wet granules, dry the granules, and mix with lubricant and the remaining amount of microcrystalline cellulose, and colloidal silicon dioxide to obtain a blend, and compress the blend into tablets
- 1 ⁇ 4 of the total amount of hydroxypropyl methylcellulose is used in step 1.
- the particle size of crospovidone is Cl-F level.
- Exemplary methods of preparation include dry powder blending, wet granulation, dry granulation by compaction/slugging, spray drying, hot melt extrusion, extrusion spheronization and fluidized bed granulation.
- the active ingredient and all the excipients in the powder formulation should have suitable particle size range and need to pass certain mesh before using, such as mesh 20, 40, 60, 80 or 100.
- Another aspect of the patent document provides a method of treating or prophylaxis or reducing the risk of a disease comprising administering the suspension prepared from tablets described herein or the whole tablet to a subject in need, wherein the disease is selected from the group consisting of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE), major cardiovascular events (cardiovascular (CV) death, myocardial infarction (MI) and stroke) in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).
- the disease is selected from the group consisting of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE), major cardiovascular events (cardiovascular (CV) death, myocardial infarction (MI) and stroke) in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).
- the disease is selected from the group consist
- Formulation compositions of rivaroxaban tablets with different types of disintegrants were prepared and shown in Table 1.
- the tablets were prepared by dry blend approach.
- the formulation with Kollidon CL-F has a short disintegration time.
- the disintegrant levels in the range 6.18% to 11.5% did not have any significant effect on the disintegration time and dissolution of tablet. However, the disintegration time of these formulation is too long (>100 s).
- Formulation 4 were prepared with different processes as following:
- Process 1 Half of binder was dissolved in granulation liquid while the other half was in the internal phase to form dry blend.
- Process 2 All the of binder was in the internal phase to form dry blend.
- Process 3 All the of binder was dissolved in granulation liquid.
- Process 1 significantly shorten the integration time of the tablet compared to process 3 (33 s vs. 114 s). And the tablet with process 2 do not has an acceptable assay (93.7%).
- the formulation with different levels of binder was prepared and shown in table 4.
- the tablets were prepared by dividing binder into two parts, 0.75 mg binder was dissolved in granulation liquid and the rest binder was in the dry blend.
- formulation 9 does not have an acceptable dissolution profile (Q ⁇ 75%). Therefore, the binder range in the formulation was between 1% -3.5%.
- Magnesium Stearate is a hydrophobic lubricant and Sodium Stearyl Fumarate is a hydrophilic lubricant.
- the formulation 20 with Magnesium Stearate has a longer DT and the formulation with Sodium Stearyl Fumarate ranging 1.3%-2.2% do not show any difference in terms of DT and dissolution.
- the process for formulation 23 is as following:
- Step 1 Dissolve SLS and partial Hypromellose ES (1 ⁇ 4) in certain amount of water to form solution 1
- Step 2 Pass internal phase excipient through certain mesh and add them into high shear granulator Step 3 Pre-mix the internal phase excipient before adding granulation liquid
- Step 4 Add granulation fluid into excipient at certain speed while mixing Step 5
- the kneading step was added for certain time
- Step 6 The wet mass pass through mill and then was dried in the fluid bed or oven under certain temperature
- Step 7 The dried granule pass through mill with screen of certain orifice Step 8
- the screened granules were mixed with external phase before compressed into tablets.
- Step 9 The final blend was compressed into tablets with average hardness 40 ⁇ 5 N
- Rivaroxaban The formulation with different strength of Rivaroxaban was prepared and shown in table 8. All the formulations have acceptable DT, assay and dissolution profile.
Abstract
Description
- This patent document discloses a novel formulation of rivaroxaban or its pharmaceutically acceptable salt, a method for its preparation and its use in medical therapy.
- Rivaroxaban is marketed in the United States by Janssen Pharmaceuticals, Inc., under the trade name XARELTO®, XARELTO is for the indication of reducing the risk of stroke and blood clots, treating blood clots in the veins, helping prevent blood clots, and also reducing the risk of serious heart problems, heart attack and stroke in people with coronary artery disease. XARELTO is an immediate release tablet. There are no liquid formulations of rivaroxaban commercially available and, as a result, pharmacists are often required to compound liquid formulations using crushed rivaroxaban tablets for pediatric patients and patients who cannot swallow tablets, for example, acutely ill medical patients who need medicine administered via an NG tube or gastric feeding tube. A need exists for an improved formulation of Rivaroxaban.
- Tablets for oral suspension formulation described herein allows for convenient oral administration of Rivaroxaban. The formulation resolved the dose inaccuracy issue due to the crushed step and precipitation of big crushed particles in a suspension system, Furthermore, tablets for oral suspension do not require professionals to crush the tablet and can be dispersed in the vehicles to form suspension immediately before use, which is much convenient for patients and professionals. Moreover, the tablets for oral suspension formulation substantially improves the stability of the medication compared to the ready-to-use suspension.
- An aspect of this patent document provides tablets for oral suspension formulation suitable for reconstitution with a pharmaceutically acceptable carrier to form a suspension. The formulation contains rivaroxaban or a pharmaceutically acceptable salt thereof, and excipients including for example disintegrant agent, lubricant, glidant, binder, wetting agent, and filler. The rivaroxaban tablets for oral suspension can disintegrate rapidly within about 3 minutes in 100 ml water at room temperature, and the reconstituted suspension can pass through mesh aperture of 710 μm, furthermore, the tablet provides an in vitro release of at least about 75% of the rivaroxaban within about 30 minutes under USP dissolution apparatus 2, in 900 ml of pH14.5 media (2.5 mg) or with 0.2% SLS (for 10 mg strength) or 0.4% SLS (for 15 mg and 20 mg strength) at 75 rpm stirring rate.
- In some embodiments, rivaroxaban or a pharmaceutically acceptable salt is present ranging about 1 mg to about 50 mg in the tablet.
- In some embodiments, rivaroxaban or a pharmaceutically acceptable salt is present ranging about 1% to about 30% in the tablet.
- In some embodiments, the disintegrant agent is present ranging from about 5% to about 15% in the tablet.
- In some embodiments, the ubricant is present ranging from about 0.5% to about 5% in the tablet.
- In some embodiments, the glidant is present ranging from about 0.5% to about 3% in the tablet.
- In some embodiments, the wetting agent is present ranging from about 0.1% to about 1% in the tablet.
- In some embodiments, the binder is present ranging from about 1% to abort 8% in the tablet.
- In some embodiments, the rivaroxaban or the pharmaceutically acceptable salt thereof and the wetting agent have a ratio ranging from about 20:0.1 to about 1:1 by weight.
- In some embodiments, the rivaroxaban or the pharmaceutically acceptable salt thereof and the binder have a ratio ranging from about 20:0.5 to about 1:1 by weight.
- In some embodiments, the disintegrant agent is selected from starch, crosslinked polyvinylpyrrolidone (crospovidone), crosslinked sodium carboxymethyl cellulose (croscarmellose sodium), the modified starch sodium starch glycolate and any combination thereof. In some embodiments, the disintegrant agent is crospovidone.
- In some embodiments, the dosage form further contains a lubricant selected from the group consisting of magnesium stearate, stearic acid, sodium stearyl fumarate, and sodium lauryl sulfate, glyceryl palmitostearate, and any combination thereof. In some embodiments, the lubricant is sodium stearyl fumarate.
- In some embodiments, the formulation further contains glidants including for example silicon dioxide, starch, talc and any combination thereof. In some embodiments, the glidant is silicon dioxide.
- In some embodiments, the formulation further contains the wetting agent including for example sodium dodecyl sulfate (SDS) or sodium lauryl sulfate (SLS), poloxamers or pluronics, tween 80 and any combination thereof. In some embodiments, the wetting agent is sodium lauryl sulfate (SLS)
- In some embodiments, the formulation further contains the binder including for example Polyvinylpyrrolidone (PVP), Hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC) and any combination thereof. In some embodiments, the binder is Hydroxypropyl methylcellulose (HPMC).
- In some embodiments, the formulation further contains a filler selected from the group consisting of sucrose, dextrose, mannitol, sorbitol, maltitol, starch, lactose, microcrystalline cellulose, and any combination thereof in about 10% to about 98% by weight of the tablet formulation. In some embodiments, the tiller is microcrystalline cellulose and lactose, with the ratio ranging from about 5:1 to about 1:5 by weight.
- In some embodiments, the rivaroxaban or the pharmaceutically acceptable salt thereof has a D90 ranging from about 1 μm to about 50 μm prior to being mixed with the excipients.
- In some embodiments, a dosage form can be manufacture via wet granulation, dry granulation, dry blending, melt granulation and fluid bed granulation approach. In some embodiments, a dosage form can be manufactured via wet granulation approach in high shear granulator.
- In some embodiments, a dosage form can be manufacture via wet granulation by adding water in the powder in high shear granulator, the amount of water is 20% to 60% of that powder for granulation by weight.
- In some embodiments, the rivaroxaban tablets for oral suspension can disintegrate rapidly within about 3 minutes in 100 ml water at room temperature, and the reconstituted suspension can pass through mesh aperture of 710 μm.
- In some embodiments, the tablet provides an in vitro release of at least about 75% of the rivaroxaban within about 30 minutes under USP dissolution apparatus 2, in 900 ml of pH4.5 media (2.5 mg) or with 0.2% SLS (for 10 mg strength) or 0.4% SLS (for 15 mg and 20 mg strength) at 75 rpm stirring rate.
- In some embodiments, the tablets for oral suspension formulation provides a release of rivaroxaban bioequivalent to XARELTO tablet of the same dose. In some embodiments, the suspension prepared from the tablet formulation provides a release of the rivaroxaban bioequivalent to a non-suspension dosage form (e.g. XARELTO tablet), which provides a therapeutically effective blood concentration of rivaroxaban.
- Another aspect of the patent document provides a method of treating or prophylaxis or reducing the risk of a disease comprising administering the suspension described herein to a subject in need, wherein the disease is selected from the group consisting of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE), major cardiovascular events (cardiovascular (CV) death, myocardial infarction (MI) and stroke) in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).
- This document discloses a tablet formulation suitable for reconstitution with a pharmaceutically acceptable carrier to form a suspension oral dosage form of rivaroxaban. Advantages of the tablets for oral suspension formulation include avoiding tablet crushing, dose accuracy and better compliance for pediatric patients and patients who cannot swallow tablets in comparison with conventional immediate release non-suspension dosage forms.
- Rivaroxaban is known as 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide. Rivaroxaban is insoluble in water. When crushed rivaroxaban tablets are simply added directly into water or other soft food, the compound tends to settle rapidly and cannot be easily redistributed and as such would potentially affect the dose accuracy delivered to a patient.
- The tablets for oral suspension formulation disclosed herein effectively resolved the above issues. After reconstitution, the suspension enables easy and accurate dose for pediatric patients and patients who cannot swallow tablets, for example, acutely ill medical patients who need medicine administered via an NG tube or gastric feeding tube. Further, tablets for oral suspension formulation substantially improves the stability of the medication compared to the ready-to-use suspension. The table for oral suspension formulation described in this patent document are applicable to Rivaroxaban as well as salts, isomers, complexes, polymorphs, hydrates, esters and prodrugs thereof.
- While the following text may reference or exemplify specific embodiments of a dosage form or a method of manufacturing the dosage from, it is not intended to limit the scope of the dosage form to such particular reference or examples. Various modifications may be made by those skilled in the art, in view of practical and economic considerations, such as the amount of individual excipients and the manufacturing condition.
- The articles “a” and “an” as used herein refers to “one or more” or “at least one,” unless otherwise indicated. That is, reference to any element or component of an embodiment by the indefinite article “a” or “an” does not exclude the possibility that more than one element or component is present.
- The term “about” as used herein refers to the referenced numeric indication plus or minus 10% of that referenced numeric indication.
- The term “active ingredient” or “active pharmaceutical ingredient” (API) refers to a compound (e.g. rivaroxaban) that can be used for treating a disorder or condition in a subject (e.g., a patient), or for preventing one or more symptoms of such disorder or condition in the subject.
- The term “bioequivalence” or “bioequivalent” refers to two formulations, dosage forms, products, or compositions of an active ingredient having biological equivalence. It is generally considered bioequivalent if the 90% Confidence Interval (“CI”) of the relative mean Cmax, AUC(0-t) and AUC(0-∞) of the test formulation to reference formulation (i.e., brand product) is within 80.0% to 125.0% in the fasting state of a tested subject.
- The term “patient compliance” refers to the degree to which patient correctly follows medical advice.
- The term “excipient” refers to any inert substance that may have specific functions to the active ingredient (e.g., filler agent, binder, lubricant, glidant). An excipient provides without limitation, bulk, consistency, stability, binding ability, lubrication, disintegrating ability, etc., to the formulation of an active ingredient. A “glidant” is a type of excipient. An excipient may function for multiple purposes.
- The term “powder” as used herein refers to any composition or formulation which is dry and flowable. Non-limiting examples include granules, flakes, spheroids and other forms which can be readily prepared and mixed with an ingestible liquid to provide a desirable liquid suspension.
- The term “wet granulation” refers to a process of using a liquid binder to lightly agglomerate the powder mixture.
- The term “API” refer to active pharmaceutical ingredient, which is rivaroxaban or a pharmaceutically acceptable salt.
- The term “release”, “released”, “releasing”, and the like, when used in connection with a pharmaceutical compression or dosage form, refers to the process or the portion of the active ingredient that leaves the dosage form following contact with an aqueous environment. Unless otherwise indicated, the quantity of an active ingredient released from a dosage form is measured by dissolution testing in water as described in this invention. The results of the dissolution testing are reported as % (w/w) released as a function of time or as the release time. In some embodiments, complete release of an active ingredient occurs when at least 90% of the active ingredient has been released from the dosage form.
- The term “immediate-release” refers to those which disintegration rapidly and/or get dissolved to release the medicaments or active ingredient.
- The term “Cmax” or “peak plasma exposure”, expressed in ng/mL, refers to the point of maximum concentration of drug in plasma.
- The term “area under curve (AUC)” or “total plasma exposure”, expressed in μg·hr/mL, refers to the total integrated area under plasma level time profile and expresses the total amount of the active ingredient that comes into systemic circulation after administration.
- The term “D90” refers to the particle size corresponding to 90% of the cumulative undersize distribution by volume.
- The term “pharmaceutically acceptable carrier” refers to an agent or a substance that enable an active ingredient or a composition thereof to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for administration to a subject in need. For example, the carrier can be water or an aqueous solution containing other excipients.
- The term “subject” refers to a mammal, such as an animal or a human. Hence, the methods disclosed herein can be useful in human therapy and veterinary applications. In one embodiment, the subject is an animal. In another embodiment, the subject is a human.
- The term “treat” or “treating” refers to attain or attaining a beneficial or desired result, such as a clinical result. In some embodiments, the beneficial or desired result is any one or more of the following: inhibiting or suppressing the onset or development of a condition, reducing the severity of the condition, reducing the number or severity of symptoms associated with the condition, increasing the quality of life of a patient suffering from the condition, decreasing the dose of another medication required to treat the condition, enhancing the effect of another medication a patient is taking for the condition, and prolonging the survival of a patient having the condition.
- An aspect of the document provides tablets for oral suspension formulation suitable for reconstitution with a pharmaceutically acceptable carrier to form an oral suspension of rivaroxaban. The formulation includes:
- Rivaroxaban, a pharmaceutically acceptable salt, an isomer, a complex, a polymorph, a hydrate, or an ester thereof:
- Disintegrant agent present ranging from about 5% to about 15%
- Lubricant agent present ranging from about 0.5% to about 5%
- Glidant agent present ranging from about 0.5% to about 3%
- Wetting agent present ranging from about 0.1% to about 1%
- Binder present ranging from about 1% to about 8%
- Filler ranging from about 10% to about 98% by weight
- Wetting agent, having a ratio with rivaroxaban or the pharmaceutically acceptable salt ranging from about 20:0.1 to about 1:1 by weight.
- Binder, having a ratio with rivaroxaban or the pharmaceutically acceptable salt ranging from about 20:0.5 to about 1:1 by weight.
- In some embodiments. the pharmaceutically acceptable carrier is water or an aqueous solution containing one or more agents or excipients.
- The rivaroxaban tablets for oral suspension can disintegrate rapidly within about 3 minutes (e.g. 160 seconds, 140 seconds, 120 seconds, 90 seconds, 60 seconds, or 30 seconds), within about 2 minutes (e.g. 100 seconds, 80 seconds. 60 seconds, or 30 seconds), or within about 1 minute (e.g. 30 seconds, 35 seconds, 40 seconds, 45 seconds, 50 seconds, or 55 seconds) in 100 ml water at room temperature, and the reconstituted suspension can pass through mesh aperture of 710 μm, furthermore, the tablet provides an in vitro release of at least about 75% of the rivaroxaban within about 30 minutes, within about 20 minutes, or within about 10 minutes under USP dissolution apparatus 2, in 900 ml of ph 4.5 media (2.5 mg) or with 0.2% SLS (for 10 mg strength) or 0.4% SLS (for 15 mg and 20 mg strength) at 75 rpm stirring rate.
- In some embodiments, rivaroxaban or a pharmaceutically acceptable salt is present ranging from 1 mg to 50 mg. In some embodiments, the tablet includes 2.5-20 mg rivaroxaban or a pharmaceutically acceptable salt thereof.
- In some embodiments, the rivaroxaban or a pharmaceutically acceptable salt is present ranging from about 1% to about 30%, from about 1.5% to about 25%, from about 1.8% to about 22%, or from about 2% to about 18% by weight.
- In some embodiments, the disintegrant agent is present ranging from about 5% to about 15%, from about 5% to about 14%, from about 5% to about 13%, from about 6% to about 12%, from about 6% to about 11%, from about 6% to about 10% by weight.
- In some embodiments, the lubricant agent is present ranging from about 0.2% to about 7%, from about 0.5% to about 5%, from about 1% to about 3%, from about 1.1% to about 2.5%, from about 1.3% to about 2.2% by weight,
- In some embodiments, the glidant agent is present ranging from about 0.5% to about 3%, from about 0.6% to about 2%, from about 0.7% to about 1.5%, from about 0.8% to about 1.2% by weigh.
- In some embodiments, the wetting agent is present ranging from about 0.1% to about 1.2%, from about 0.1% to about 1%, from about 0.2% to about 0.8%, from about 0.2% to about 0.6% by weigh.
- In some embodiments, the binder is present ranging from about 1% to about 8%, from about 1% to about 3.5%, from about 1.5% to about 3.5%, from about 2% to about 3% by weigh.
- In some embodiments, the rivaroxaban or the pharmaceutically acceptable salt thereof and the wetting agent have a ratio ranging from about 20:0.1 to about 1:1, from about 20:0.2 to about 2:1, from about 20:0.3 to about 3:1, from about 20:0.4 to about 4:1 by weight.
- In some embodiments, the rivaroxaban or the pharmaceutically acceptable salt thereof and the binder have a ratio ranging from about 20:0.5 to about 1:1 by weight, from about 20:0.8 to about 1:1, from about 20:1 to about 1:1
- In some embodiments, the disintegrant agent is selected from starch, crosslinked polyvinylpyrrolidone (crospovidone), crosslinked sodium carboxymethyl cellulose (croscarmellose sodium), the modified starch sodium starch glycolate and any combination thereof. In some embodiments, the disintegrant agent is crospovidone (Kollidon CL-F).
- In some embodiments, the dosage form further contains a lubricant selected from the group consisting of magnesium stearate, stearic acid, sodium stearyl fumarate, and sodium lauryl sulfate, glyceryl palmitostearate, and any combination thereof. In some embodiments, the lubricant is sodium stearyl fumarate.
- In some embodiments, the formulation further contains glidants including for example silicon dioxide, starch, talc and any combination thereof. In some embodiments, the glidant is silicon dioxide.
- In some embodiments, the wetting agent is selected sodium dodecyl sulfate (SLS) or sodium lauryl sulfate (SLS), poloxamers or pluronics, tween 80 and any combination thereof. In some embodiments, the wetting agent is sodium dodecyl sulfate (SLS).
- In some embodiments, the binder is selected from Polyvinylpyrrolidone Hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC) and any combination thereof. In some embodiments, the binder is Hydroxypropyl methylcellulose (HPMC).
- In some embodiments, the formulation further contains a filler selected from the group consisting of sucrose, dextrose, mannitol, sorbitol, maltitol, starch, lactose, microcrystalline cellulose, and any combination thereof in about 10% to about 98%, from about 30% to about 95%, from about 45% to about 93%, from about 60% to about 90% by weight. In some embodiments, the filler is microcrystalline cellulose and lactose, with the ratio ranging from about 5:1 to about 1:5, from about 4:1 to about 1:2, from about 3:1 to about 1:1, from about 2:1 to about 1: 1 by weight.
- In some embodiments, the tablet has an inner phase and an external phase. The inner phase includes rivaroxaban, hydroxypropyl methylcellulose, sodium lauryl sulfate, crosslinked polyvinylpyrrolidone (crospovidone), 70-95% of the total microcrystalline cellulose, and lactose monohydrate, while the external phase includes the remaining amount of microcrystalline cellulose, colloidal silicon dioxide and lubricant. In some embodiments, the ratio between the microcrystalline cellulose and the lactose monohydrate ranges from 1:1 to 2:1 or from 1.5-1.8:1 by weight. In some embodiments, substantially all of the lactose monohydrate is in the inner portion.
- In some embodiments, the tablet by weight includes 1.0%-30.0% rivaroxaban, 1,0%-8.0% hydroxypropyl methylcellulose, 0.1-1% sodium lauryl sulfate, 5%-15.0% crosslinked polyvinylpyrrolidone (crospovidone), 0.5%-3.0% colloidal silicon dioxide, 0.5%-5% lubricant (e.g. magnesium stearate or sodium stearvl fumarate), and filler (e.g. microcrystalline cellulose and the lactose monohydrate).
- In some embodiments, the tablet by weight includes 1.5%-25.0% rivaroxaban, 1.0%-5.0% hydroxypropyl methylcellulose, 0.2-0.8% sodium lauryl sulfate, 6.0%12.0% crosslinked polyvinylpyrrolidone (crospovidone), 0.6%-2.0% colloidal silicon dioxide, 1.0%-3.0% sodium stearyl fumarate, and microcrystalline cellulose and the lactose monohydrate as filler.
- In some embodiments, the tablet by weight includes 1.8%-22.0% rivaroxaban, 1.5%-3.5% hydroxypropyl methylcellulose, 0.2-0.8% sodium lauryl sulfate, 6.0%-12.0% crosslinked polyvinylpyrrolidone (crospovidone), 0.7%-4.5% colloidal silicon dioxide, 1.1%-2.5% sodium stearyl fumarate, and microcrystalline cellulose and the lactose monohydrate as filler.
- In some embodiments, the tablet by weight includes 2.0%-18.0% rivaroxaban, 2.0%-3.0% hydroxypropyl methylcellulose, 0.2-0.6% sodium lauryl sulfate, 6.0%-10.0% crosslinked polyvinylpyrrolidone (crospovidone), 0.8%1.2% colloidal silicon dioxide, 1.3%-2.2% sodium stearvl fumarate, and microcrystalline cellulose and the lactose monohydrate as filler.
- In some embodiments, the rivaroxaban or the pharmaceutically acceptable salt thereof has a D90 ranging from about 1 μm to about 50 μm, from about 2 um to about 40 um, from about 3 um to about 30 um, from about 4 um to about 20 um prior to being mixed with the excipients.
- In some embodiments, a dosage form can be manufacture via wet granulation, dry granulation, dry blending, melt granulation and fluid bed granulation approach. In some embodiments, a dosage form can be manufactured via wet granulation approach in high shear granulator.
- In some embodiments, a dosage form can be manufactured via wet granulation by adding from about 20% to about 60%, from about 30% to about 50% of water to the powder in high shear granulator.
- The rivaroxaban tablets for oral suspension can disintegration rapidly within 3 minutes within about 2 minutes, within about 1 minutes when dispersing in the 100 ml water at room temperature.
- The tablets for oral suspension formulation provide an in vitro release as measured by USP dissolution apparatus 2. In some embodiments, at least about 95%, at least about 90%, at least about 85%, at least about 80%, at least about 75%, at least about 65% or at least about 50% of 2.5 mg rivaroxaban is released in a pH4.5 medium within about 30 minutes, within about 20 minutes, within about 10 minutes at 75 rpm stirring rate
- The tablets for oral suspension formulation provide an in vitro release as measured by USP dissolution apparatus 2. In some embodiments, at least about 95%, at least about 90%, at least about 85%, at least about 80%, at least about 75%, at least about 65% or at least about 50% of 10 mg rivaroxaban is released in a pH4.5 medium with 0.2% SLS within about 30 minutes, within about 20 minutes, within about 10 minutes at 75 rpm stirring rate
- The tablets for oral suspension formulation provide an in vitro release as measured by USP dissolution apparatus 2. In some embodiments, at least about 95%, at least about 90%, at least about 85%, at least about 80%, at least about 75%, at least about 65% or at least about 50% of 15 mg or 20 mg rivaroxaban is released in a pH4.5 medium with 0.4% SLS within about 30 minutes, within about 20 minutes, within about 10 minutes at 75 rpm stirring rate
- The tablets for oral suspension formulation can also provide a release of rivaroxaban bioequivalent to non-suspension formulation of rivaroxaban at the same dose. Examples of non-suspension formulation of rivaroxaban include rivaroxaban tablets. In some embodiments, the dose of rivaroxaban in the formulation is about 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, 40 mg or 50 mg.
- The suspension can be prepared from the above described tablets for oral suspension formulation by reconstitution or by mixing the necessary components in suitable means as long as the resulting suspension achieves a desirable profile for oral administration. For example, the suspension can be prepared by adding water to the above described tablets formulation containing suitable dosage of rivaroxaban or its salt and thoroughly mix the combined substances.
- The tablets for oral suspension allow for accurate dose and easy administration. The tablets for oral suspension formulation also have excellent stability compared to ready-to-use suspension. This is especially important for pediatric patients and patients who cannot swallow tablets, for example, acutely ill medical patients who need medicine administered via an NG tube or gastric feeding tube.
- Another aspect of the patent document provides a method of preparing the above described formulation. The method generally includes:
- Step 1 Dissolve wetting agent and partial binder (¼-½) in certain amount of water to form solution 1
Step 2 Pass internal phase excipient(including partial binder) through certain mesh and add them into high shear granulator
Step 3 Pre-mix the internal phase excipient before adding granulation liquid
Step 4 Add granulation fluid into excipient at certain speed while mixing
Step 5 After all the granulation liquid was added, the kneading step was added for certain time
Step 6 The wet mass pass through mill and then was dried in the fluid bed or oven under certain temperature
Step 7 The dried granule pass through mill with screen of certain orifice
Step 8 The screened granules mixed with external phase before compressed into tablets.
Step 9 The final blend was compressed into tablets of certain hardness. - In some embodiments, the tablet disclosed herein is prepared according to the following method:
- Step 1 Dissolve sodium lauryl sulfate and ¼-½ of total amount of hydroxypropyl methylcellulose in water to form a solution;
Step 2 mix rivaroxaban, lactose monohydrate and the remaining amount of hydroxypropyl methylcellulose to obtain a mixture;
Step 3 pass the mixture of step 2 through mesh;
Step 4 mix the mixture of step 3 with 70-95% of microcrystalline cellulose and all crospovidone to prepare granules;
Step 5 add the solution from step 1 to the granules to obtain wet granules, dry the granules, and mix with lubricant and the remaining amount of microcrystalline cellulose, and colloidal silicon dioxide to obtain a blend, and compress the blend into tablets - In some embodiments, ¼ of the total amount of hydroxypropyl methylcellulose is used in step 1. In some embodiments, the particle size of crospovidone is Cl-F level.
- Exemplary methods of preparation include dry powder blending, wet granulation, dry granulation by compaction/slugging, spray drying, hot melt extrusion, extrusion spheronization and fluidized bed granulation. As described above, in order to have good uniformity, the active ingredient and all the excipients in the powder formulation should have suitable particle size range and need to pass certain mesh before using, such as mesh 20, 40, 60, 80 or 100.
- Another aspect of the patent document provides a method of treating or prophylaxis or reducing the risk of a disease comprising administering the suspension prepared from tablets described herein or the whole tablet to a subject in need, wherein the disease is selected from the group consisting of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE), major cardiovascular events (cardiovascular (CV) death, myocardial infarction (MI) and stroke) in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).
- Formulation compositions of rivaroxaban tablets with different types of disintegrants were prepared and shown in Table 1. The tablets were prepared by dry blend approach. The formulation with Kollidon CL-F has a short disintegration time.
-
TABLE 1 The composition of formulation with different types of disintegrants 10 mg/tablet Component Formulation 1 Formulation 2 Formulation 3 Internal phase Rivaroxaban 10 10 10 Croscarmellose 10 / / Sodium Sodium Starch / 10 / Glycolate Kollidon CL-F / / 10 Hypromellose 1.5 1.5 1.5 Microcrystalline 42.17 42.17 42.17 Cellulose Lactose Monohydrate 33.73 33.73 33.73 Colloidal Silicon 1.1 1.1 1.1 Dioxide Sodium Lauryl 0.5 0.5 0.5 Sulphate External phase Sodium Stearyl 2 9 2 Fumarate Microcrystalline 11.1 11.1 11.1 Cellulose Colloidal Silicon 1.1 1.1 1.1 Dioxide Total tablet weight 113.2 113.2 113.2 Disintegration time 32 s 28 s 17 s - The formulation with different levels of disintegrant (Kollidon CL-F) was prepared and shown in table 2.
-
TABLE 2 The composition of formulation with different levels of disintegrant 10 mg/tablet Component Formulation 4 Formulation 5 Formulation 6 Internal phase Rivaroxaban 10 10 10 Kollidon CL-F 10 (8.8%) 7 (6.18%) 13 (11.5%) Hypromellose 1.5 1.5 1.5 Microcrystalline 42.17 43.67 40.67 Cellulose Lactose Monohydrate 33.73 35.23 32.23 Colloidal Silicon 1.1 1.1 1.1 Dioxide Sodium Lauryl 0.5 0.5 0.5 Sulphate External phase Sodium Stearyl 9 2 2 Fumarate Microcrystalline 11.1 11.1 11.1 Cellulose Colloidal Silicon 1.1 1.1 1.1 Dioxide Total tablet weight 113.2 113.2 113.2 Disintegration time 114 s 108 s 125 s Dissolution (Q at 100.4% 96.0% 100.5% 30 min) - The process is as follows:
- (1) Sodium Lauryl Sulphate and Hyprornellose were dissolved in water to form solution 1.
(2) The internal phase (Rivaroxaban, Lactose Monohydrate and Colloidal Silicon Dioxide) was mixed and sieved
(3) The above mixture was added into high sheer mixer and mixed for 3 min
(4) A wet granulation was carried out by adding solution 1 to the dry mixtures within 5 min.
(5) The wet granule was milled and dried in a fluid bed dryer
(6) The dry granule was milled and mixed with external phase
(8) The final blend was compressed into tablets with average hardness 40±5 N. - The disintegrant levels in the range 6.18% to 11.5% did not have any significant effect on the disintegration time and dissolution of tablet. However, the disintegration time of these formulation is too long (>100 s).
- Formulation 4 were prepared with different processes as following:
- Process 1: Half of binder was dissolved in granulation liquid while the other half was in the internal phase to form dry blend.
Process 2: All the of binder was in the internal phase to form dry blend.
Process 3: All the of binder was dissolved in granulation liquid. -
TABLE 3 The process effect on tablet disintegration time and dissolution Process 1 Process 2 Process 3 Assay 99.4% 93.7% 100.5% Disintegration 33 s 35 s 114 s time Dissolution 99.7% 92.9% 100.4% (Q at 30 min) - Process 1 significantly shorten the integration time of the tablet compared to process 3 (33 s vs. 114 s). And the tablet with process 2 do not has an acceptable assay (93.7%).
- The formulation with different levels of binder (Hypromellose) was prepared and shown in table 4. The tablets were prepared by dividing binder into two parts, 0.75 mg binder was dissolved in granulation liquid and the rest binder was in the dry blend.
-
TABLE 4 The composition of formulation for different levels of binder 20 mg/tablet Component Formulation 9 Formulation 10 Formulation 11 Formulation 12 Internal phase Rivaroxaban 20 20 2.0 20 Kollidon CL-F 10 10 10 10 Hypromellose 0 1 2 3.5 Microcrystalline 40.74 40.26 39.65 38.74 Cellulose Lactose 26.66 26.14 27.75 25.16 Monohydrate Sodium Lauryl 0.6 0.6 0.6 0.6 Sulphate External phase Sodium Stearyl 9 9 2 9 Fumarate Total tablet weight 100 100 100 100 Assay 103.8% 98.1% 98.0% 104.4% Disintegration time 22 s 47 s 62 s 86 s (DT) Dissolution 68.9% 94.0% 98.7% 98.6% (Q at 30 min) - All the formulation has the acceptable DT (<90 s), and increasing binder amount in the formulation increase the disintegration time. However, without binder, formulation 9 does not have an acceptable dissolution profile (Q<75%). Therefore, the binder range in the formulation was between 1% -3.5%.
- The formulation with different ratio of filler (MCC and lactose monohydrate) was prepared and shown in table 5.
-
TABLE 5 The formulation composition of different ratio of MCC/Lactose Monohydrate 20 mg/tablet Formulation Formulation Formulation Formulation Formulation 13 14 15 16 17 Component (1.96:1) (1.96:1) (1.54:1) (1:1) (1:1.54) Internal phase Rivaroxaban 20 20 20 20 20 Kollidon CL-F 10 10 10 10 10 Hypromellose 1 1 1 1 1 Microcrystalline 40.26 40.26 40.26 33.20 26.14 Cellulose(MCC) Lactose 26.14 26.14 26.14 33.20 40.26 Monohydrate Sodium Lauryl 0.6 0.6 0.6 0.6 0.6 Sulphate External phase Sodium Stearyl 2 2 2 2 2 Fumarate Microcrystalline 11.1 11.1 — — — Cellulose Colloidal Silicon — 1.1 — — — Dioxide Total tablet 111.1 112.2 100 100 100 weight Disintegration 52 s 44 s 64 s 83 s 103 s time (DT) Dissolution 99.25% 99.25% 98.0% 97.3% 95.6% (Q at 30 min) - The result showed external phase of MCC and Colloidal Silicon Dioxide (formulation 14) can shorten Disintegration time (44 s). The lower the ratio of MCC/Lactose Monohydrate, the longer DT is. The DT of tablet was 103 s when the MCC/Lactose ratio is 1:1.54 (formulation 17), which is not acceptable.
- The formulation with different types and levels of lubricant was prepared and shown in table 7. Magnesium Stearate is a hydrophobic lubricant and Sodium Stearyl Fumarate is a hydrophilic lubricant. The formulation 20 with Magnesium Stearate has a longer DT and the formulation with Sodium Stearyl Fumarate ranging 1.3%-2.2% do not show any difference in terms of DT and dissolution.
-
TABLE 6 The composition of different types and levels of lubricant 10 mg/tablet Component Formulation 20 Formulation 21 Formulation7 Formulation 22 Internal phase Rivaroxaban 10 10 10 10 Kollidon CL-F 10 10 10 10 Hypromellose E5 1.5 1.5 1.5 1.5 Microcrystalline 42.17 42.17 42.17 42.17 Cellulose Lactose 33.73 33.73 33.73 33.73 Monohydrate Colloidal Silicon 1.1 1.1 1.1 1.1 Dioxide Sodium Lauryl 0.5 0.5 0.5 0.5 Sulphate External phase Magnesium 2 / / / Stearate Sodium Stearyl / 1.5 2 2.5 Fumarate Microcrystalline 11.1 11.6 11.1 10.6 Cellulose Colloidal Silicon 1.1 1.1 1.1 1.1 Dioxide Total tablet weight 113.2 113.2 113.2 113.2 Disintegration time 50 s 31 s 33 s 31 s (DT) Dissolution 100.4% 101.1% 99.7% 98.8% (Q at 30 min) - The formulation with different levels of Colloidal Silicon Dioxide was prepared and shown in table 6. All the formulations have acceptable DT, assay and dissolution profile. However, in the scale up, formulation 7 has a low assay (<90%) while formulation 23 without internal Colloidal Silicon Dioxide has a good assay (100.4%)
-
TABLE 7 The composition of different levels of Colloidal Silicon Dioxide 10 mg/tablet Component Formulation 7 Formulation 18 Formulation 19 Formulation 23 Internal phase Rivaroxaban 10 10 10 10 Kollidon CL-F 10 10 10 10 Hypromellose E5 1.5 1.5 1.5 3 Microcrystalline 42.17 42.72 42.44 42.17 Cellulose Lactose 33.73 34.28 34.01 33.33 Monohydrate Colloidal Silicon 1.1 0 0.55 0 Dioxide Sodium Lauryl 0.5 0.5 0.5 0.5 Sulphate (SLS) External phase Sodium Stearyl 2 9 2 2 Fumarate Microcrystalline 11.1 11.1 11.1 11.1 Cellulose Colloidal Silicon 1.1 1.1 1.1 1.1 Dioxide Total tablet weight 113.2 113.2 113.2 113.2 Disintegration time 33 s 53 s 45 s 55 s (DT) Dissolution 99.7% 101.1% 99.4% 100.4% (Q at 30 min) - The process for formulation 23 is as following:
- Step 1 Dissolve SLS and partial Hypromellose ES (¼) in certain amount of water to form solution 1
Step 2 Pass internal phase excipient through certain mesh and add them into high shear granulator
Step 3 Pre-mix the internal phase excipient before adding granulation liquid
Step 4 Add granulation fluid into excipient at certain speed while mixing
Step 5 After all the granulation liquid was added, the kneading step was added for certain time
Step 6 The wet mass pass through mill and then was dried in the fluid bed or oven under certain temperature
Step 7 The dried granule pass through mill with screen of certain orifice
Step 8 The screened granules were mixed with external phase before compressed into tablets.
Step 9 The final blend was compressed into tablets with average hardness 40±5 N - The formulation with different strength of Rivaroxaban was prepared and shown in table 8. All the formulations have acceptable DT, assay and dissolution profile.
-
TABLE 8 The composition of formulation with different strength mg/tablet Component 2.5 10 15 20 Internal phase Rivaroxaban 2.5 10 15 20 Kollidon CL-F 10 10 10 10 Hypromellose 3 3 3 3 Microcrystalline 46.67 42.17 39.38 36.58 Cellulose Lactose 36.33 33.33 31.12 28.92 Monohydrate Sodium Lauryl 0.5 0.5 0.5 0.5 Sulphate External phase Sodium Stearyl 2.0 2.0 2.0 2.0 Fumarate Microcrystalline 11.1 11.1 11.1 11.1 Cellulose Colloidal Silicon 1.1 1.1 1.1 1.1 Dioxide Total tablet weight 113.2 113.2 113.2 113.2 - While the invention has been disclosed in some detail by way of illustration and example for purposes of clarity of understanding, it is apparent to those in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. Therefore, the description and examples should not be construed as limiting the scope of the invention.
Claims (25)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110704987.5 | 2021-06-24 | ||
CN202110704987.5A CN113425729B (en) | 2021-06-24 | 2021-06-24 | Rivaroxaban-containing pharmaceutical composition and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220409626A1 true US20220409626A1 (en) | 2022-12-29 |
Family
ID=77754232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/501,519 Pending US20220409626A1 (en) | 2021-06-24 | 2021-10-14 | Tablets for oral suspension containing rivaroxaban |
Country Status (3)
Country | Link |
---|---|
US (1) | US20220409626A1 (en) |
CN (1) | CN113425729B (en) |
WO (1) | WO2022267169A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114081866A (en) * | 2021-11-08 | 2022-02-25 | 则正(上海)生物科技有限公司 | Method for evaluating internal and external correlation of glipizide tablets |
CN114767645B (en) * | 2022-04-27 | 2024-04-05 | 北京斯利安药业有限公司 | Folic acid tablet and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150037415A1 (en) * | 2003-11-27 | 2015-02-05 | Bayer Intellectual Property Gmbh | Process for the preparation of a solid, orally administrable pharmaceutical composition |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103550165B (en) * | 2013-10-19 | 2019-07-16 | 浙江华海药业股份有限公司 | A kind of pharmaceutical composition and preparation method thereof containing razaxaban |
WO2015124995A1 (en) * | 2014-02-19 | 2015-08-27 | Aurobindo Pharma Ltd | Solid dosage forms of rivaroxaban |
CN105078997A (en) * | 2014-05-19 | 2015-11-25 | 广东东阳光药业有限公司 | Rivaroxaban pharmaceutical composition and preparation method thereof |
CN104055743B (en) * | 2014-06-10 | 2016-01-06 | 吉林省博大制药有限责任公司 | A kind of preparation method containing razaxaban oral formulations |
CN104042580B (en) * | 2014-06-17 | 2016-08-24 | 珠海润都制药股份有限公司 | A kind of valsartan dispersible tablet and preparation method thereof |
CN106265547A (en) * | 2015-05-12 | 2017-01-04 | 北京济美堂医药研究有限公司 | A kind of preparation method of the razaxaban pharmaceutical composition improving production technology |
CN105287414A (en) * | 2015-10-21 | 2016-02-03 | 南京百迪尔生物医药有限公司 | Solid drug composition containing rivaroxaban and preparation method thereof |
CN107773548A (en) * | 2016-08-30 | 2018-03-09 | 重庆植恩药业有限公司 | Solid composite containing razaxaban and preparation method thereof |
JP6574041B2 (en) * | 2017-12-15 | 2019-09-11 | エルメッド株式会社 | Rivaroxaban-containing pharmaceutical composition |
CN110652499A (en) * | 2018-06-28 | 2020-01-07 | 北京万全德众医药生物技术有限公司 | Valsartan orally disintegrating tablet |
CN110946835A (en) * | 2018-09-27 | 2020-04-03 | 海南先声药业有限公司 | Rivaroxaban solid dispersible tablet and preparation method thereof |
EP3799864B1 (en) * | 2019-10-02 | 2023-03-01 | Intas Pharmaceuticals Limited | Essentially sodium-free effervescent solid pharmaceutical compositions |
EP4185298A1 (en) * | 2019-10-10 | 2023-05-31 | Santa Farma Ilaç Sanayi A.S. | A unique granulation process for rivaroxaban containing granules |
CN111297822A (en) * | 2019-12-20 | 2020-06-19 | 青岛黄海制药有限责任公司 | Rivaroxaban pellet capsule and preparation method thereof |
CN110898021B (en) * | 2019-12-27 | 2020-11-10 | 瀚晖制药有限公司 | Irbesartan hydrochlorothiazide composite preparation and preparation method thereof |
-
2021
- 2021-06-24 CN CN202110704987.5A patent/CN113425729B/en active Active
- 2021-07-28 WO PCT/CN2021/108796 patent/WO2022267169A1/en unknown
- 2021-10-14 US US17/501,519 patent/US20220409626A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150037415A1 (en) * | 2003-11-27 | 2015-02-05 | Bayer Intellectual Property Gmbh | Process for the preparation of a solid, orally administrable pharmaceutical composition |
Also Published As
Publication number | Publication date |
---|---|
WO2022267169A1 (en) | 2022-12-29 |
CN113425729A (en) | 2021-09-24 |
CN113425729B (en) | 2022-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5908505B2 (en) | Deferasirox dispersible tablets | |
US20190008758A1 (en) | Lacosamide controlled release formulation | |
JP4868695B2 (en) | Oral preparation with good disintegration | |
JP6043281B2 (en) | Pharmaceutical composition comprising 4-amino-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1H-benzimidazol-2-yl] -1H-quinolin-2-one lactate monohydrate object | |
US20160101105A1 (en) | High drug load tablet | |
US20190054027A1 (en) | Solid Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis | |
KR20090016611A (en) | Pharmaceutical compositions of memantine | |
EP3313187B1 (en) | Sustained release formulation and tablets prepared therefrom | |
AU2022202500B2 (en) | Elagolix formulation | |
US20210161823A1 (en) | Solid oral dosage forms of eslicarbazepine | |
US20220409626A1 (en) | Tablets for oral suspension containing rivaroxaban | |
TWI418370B (en) | Dissolution-stable pharmaceutical agent | |
US20230293495A1 (en) | Pharmaceutical formulations for treating diseases mediated by kdm1a | |
JP2022078236A (en) | Ceritinib formulation | |
US10888519B2 (en) | Immediate release pharmaceutical composition of iron chelating agents | |
WO2021074808A1 (en) | Pharmaceutical composition comprising sacubitril and valsartan and process for preparation thereof | |
RU2613192C1 (en) | Tablets of clozapine with sustained release | |
US20050118256A1 (en) | Extended release alpha-2 agonist pharmaceutical dosage forms | |
US20140343076A1 (en) | Pharmaceutical compositions of lurasidone | |
EP4058025A1 (en) | Pharmaceutical compositions comprising ticagrelor | |
WO2023111187A1 (en) | Pharmaceutical compositions comprising eltrombopag | |
KR20190110771A (en) | Compact dispersible tablet comprising deferacirox | |
US11260055B2 (en) | Oral pharmaceutical composition of lurasidone and preparation thereof | |
US20200222394A1 (en) | Pharmaceutical compositions of lurasidone | |
US20130165459A1 (en) | Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SHANGHAI AUSON PHARMACEUTICALS CO., LTD., CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LU, ENXIAN;HOU, PENG;LIU, JIANJUN;REEL/FRAME:057926/0847 Effective date: 20211026 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: APPEAL BRIEF (OR SUPPLEMENTAL BRIEF) ENTERED AND FORWARDED TO EXAMINER |
|
STCV | Information on status: appeal procedure |
Free format text: EXAMINER'S ANSWER TO APPEAL BRIEF MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS |